The cluster shows conviction from asset managers but lacks insider corroboration and is offset by a $200M ATM. Monitor next 10-Q for continued institutional accumulation and whether the ATM is utilized.
Drug in focus
ARQT drug pipeline →ZORYVE
▲ Bullish Named in this fund cluster- Impact
- Phase
- Approved (commercial stage)
- Time to market
- Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
- Next catalyst
- PDUFA date · Feb 23, 2027 98d
What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $25.55entry
- T+1 · 8d ago +2.54%α +0.18% · $26.20
- T+5 · 4d ago +10.61%α +8.01% · $28.26
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Five institutional buyers accumulated $25.0M in ARQT during Q3 2026, led by Principal Financial Group doubling its stake to $21.2M, while two sellers trimmed $3.4M. The cluster follows Q3 earnings that showed ZORYVE revenue growing 45% YoY to $143.9M and raised full-year guidance, though GAAP EPS of $0.06 missed consensus. The net buying signal is tempered by the 45-day reporting lag, the concurrent $200M ATM equity program, and the absence of insider open-market buying.
Key Financial Metrics
Institutional Positions
Net institutional flow: $21.6M
▲ Buyers (5)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Principal Financial Group | DOUBLED | +337.5% | $21.2M | $16.4M |
| Bank Of New York Mellon | ADD | +80.6% | $15.8M | $7.1M |
| Barclays | ADD | +67.4% | $2.1M | $858.0K |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citigroup | TRIM | -42.2% | $4.0M | -$1.7M |
| Vontobel Holding | TRIM | -44.5% | $4.0M | -$1.8M |
Key Facts
- 5 institutional buyers added $25.0M in net new positions during Q3 2026
- Principal Financial Group doubled its stake (+337.5% shares) to $21.2M
- Bank Of New York Mellon added 80.6% to reach $15.8M
- 2 sellers (Citigroup, Vontobel) trimmed a combined $3.4M
- No insider open-market buying; insider activity shows 4 sells totaling $1.6M in the 30 days before the snapshot
- Q3 2026 ZORYVE revenue $143.9M (+45% YoY) beat consensus; GAAP EPS $0.06 missed $0.17 consensus
- $200M ATM equity program filed on same day as earnings
Financial Impact
5 institutions accumulated $25.0M in new positions while 2 reduced holdings by $3.4M; net buying of $21.6M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound
- No insider open-market buying to corroborate institutional conviction
- $200M ATM equity program could dilute existing holders if utilized
- GAAP EPS miss suggests profitability still below consensus expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ARQT-2026-Q3 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Viewing Entry $25.55 settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers